Jason J. Luke, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (NCT04056910) | Jason J. Luke, MD | 2021-09-20 |
| Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (NCT04655157) | Jason J. Luke, MD | 2021-05-28 |
Track Jason J. Luke, MD automatically
Every clearance here is in the API, with alerts when new ones post.